Xechem CEO, Dr. Ramesh Pandey to Present at the 10th Annual New York Society of Security Analysts Biotech/Specialty Pharma Industry Conference
Xechem International, Inc. (OTC BB: XKEM), Dr. Ramesh C. Pandey, the Chairman and CEO of Xechem International, will present at the 10th Annual New York Society of Security Analysts Biotech/Specialty Pharma Industry Conference in New York City on Tuesday, December 12th, 2006. He is scheduled to speak at 3:10 pm (EST). Dr. Pandey’s presentation will cover the significant progress in Nigeria for production and distribution of Xechem’s recently approved Sickle Cell drug NICOSAN™. In addition, Dr. Pandey will discuss Xechem’s new Sickle Cell product 5-HMF, a small-molecular compound, which has shown great promise in the preliminary studies with transgenic (Tg) mice, that will be developed as an injectable for acute episodes. Dr. Pandey’s presentation will be webcast live through a link on the Xechem website (www.xechem.com).
NICOSAN™ is an anti-sickling drug developed by Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD’s auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN™ no longer experience sickle cell “crises” while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced.
5-HMF is a pure natural compound developed by Professor Donald Abraham and his group at Virginia Commonwealth University (VCU). Studies carried out at VCU and Children’s Hospital of Philadelphia (CHOP) has shown 5-HMF has high affinity for sickle cell haemoglobin and thus the most promising molecule to treat Sickle Cell Disease (SCD). Preliminary animal studies show that 5-HMF is orally active with high bioavailability and has high red cell membrane permeability with very little, if any, toxicity. Xechem has license for 5-HMF from VCU for research, development, worldwide sales and marketing. Xechem received Orphan Drug Designation for 5-HMF from US-FDA on June 6th, 2006.
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antidiabetic, antimalarial, antibacterial, antifungal, anticancer and antiviral (including AIDS) products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem’s mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN™ (to be marketed as HEMOXIN™ in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem is now working on the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN™, Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University (VCU).
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties.